Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 10/20 | 0.52 |
| ▸ | TDO2 | P48775 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8998987 | 0.94 | EGFR (0.72) | EGFRHTTHSD17B10IDO1TDO2 | |
| SCHEMBL1302976 | 0.89 | EGFR (0.69) | EGFRHSD17B10IDO1TDO2GAA | |
| SCHEMBL29437202 | 0.89 | EGFR (0.69) | EGFRHSD17B10IDO1TDO2GAA | |
| Oxindole SCHEMBL3201159 | 0.83 | EGFR (0.57) | EGFRHTTHSD17B10IDO1TDO2 | |
| SCHEMBL320134 | 0.81 | IDO1 (0.57) | EGFRHTTHSD17B10IDO1TDO2 | |
| SCHEMBL28573090 | 0.81 | MAPT (0.59) | EGFRHSD17B10IDO1TDO2GAA | |
| SCHEMBL5279457 | 0.80 | IDO1 (0.59) | EGFRIDO1TDO2GAAMAPT | |
| SCHEMBL1388345 | 0.79 | EGFR (1.00) | EGFRHTTHSD17B10IDO1TDO2 | |
| SCHEMBL8999189 | 0.78 | IDO1 (0.55) | EGFRIDO1TDO2GAAMAPT | |
| SCHEMBL10789721 | 0.78 | IDO1 (0.66) | EGFRIDO1TDO2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119619358-A | Metabolic marker for detecting novel coronavirus combined with Epstein-Barr virus infection and application thereof | 湖北医药学院附属襄阳市第一人民医院 | 2025-03-14 | — | — | CN | disclosed |
| US-20100041900-A1 | Isolation of lactam compound from adlay bran and its use on anti-proliferative cancer cells | KUANG TA FOODS CO., LTD (TW) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041900-A1 | Isolation of lactam compound from adlay bran and its use on anti-proliferative cancer cells | MLX, BROX, TOP1 | EGFR 544/4885HTT 4839/4885HSD17B10 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.